Ultrasound‑targeted microbubble destruction‑mediated miR‑767 inhibition suppresses tumor progression of non‑small cell lung cancer

Li,Xiaohua; Xu,Min; Lv,Wenyu; Yang,Xingwang

doi:10.3892/etm.2020.8602

Ultrasound‑targeted microbubble destruction‑mediated miR‑767 inhibition suppresses tumor progression of non‑small cell lung cancer

Authors:
- Xiaohua Li
- Min Xu
- Wenyu Lv
- Xingwang Yang
View Affiliations

Affiliations: Department of Ultrasonography, Zibo City Linzi District People's Hospital, Zibo, Shandong 255400, P.R. China, Department of Pediatric Surgery, Burns and Plastic Surgery, and Hemorrhoids Fistula Surgery, Yidu Central Hospital of Weifang, Shandong 262500, P.R. China, Department of Oncology, Boxing People's Hospital, Binzhou, Shandong 256500, P.R. China, Department of General Surgery, Zibo City Linzi District People's Hospital, Zibo, Shandong 255400, P.R. China
Published online on: March 12, 2020 https://doi.org/10.3892/etm.2020.8602
Pages: 3391-3397

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) have important roles in tumor progression in various human cancers. Ultrasound‑targeted microbubble destruction (UTMD)‑mediated gene transfection has been considered a useful tool for improving cancer treatment. The present study aimed to investigate the role of miR‑767 in non‑small cell lung cancer (NSCLC) and further analyze the effects of UTMD‑mediated miR‑767 inhibition on tumor progression. The expression of miR‑767 was measured by reverse transcription‑quantitative PCR. UTMD‑mediated miR‑767 inhibition was achieved by the co‑transfection of microbubbles and miR‑767 inhibitor in NSCLC cells. Cell proliferation was assessed by a CCK‑8 assay and cell migration and invasion were examined by a Transwell assay. The expression of miR‑767 was increased in NSCLC serum, tissues and cells compared with controls. The reduction of miR‑767 in NSCLC cells led to the inhibition of cell proliferation, migration and invasion. UTMD increased the transfection efficiency of the miR‑767 inhibitor in NSCLC cells, and UTMD‑mediated miR‑767 inhibition resulted in a more significant suppressive effect on tumor cell proliferation, migration and invasion. Taken together, the results indicated that miR‑767 expression is upregulated in both NSCLC clinical samples and cells. The downregulation of miR‑767 can inhibit tumor cell proliferation, migration and invasion, and these effects are further promoted by UTMD‑mediated miR‑767 inhibition, which indicated the potential of a UTMD‑mediated miR‑767 inhibition as a novel therapeutic strategy for NSCLC treatment.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016.PubMed/NCBI View Article : Google Scholar
2	Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7(pii: 170070)2017.PubMed/NCBI View Article : Google Scholar
3	Li O, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018.PubMed/NCBI View Article : Google Scholar
4	Dejima H, Iinuma H, Kanaoka R, Matsutani N and Kawamura M: Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett. 13:1256–1263. 2017.PubMed/NCBI View Article : Google Scholar
5	Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I: EUROCARE-4 Working Group: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007.PubMed/NCBI View Article : Google Scholar
6	Li Y, Zhang X, Yang Z, Li Y, Han B and Chen LA: miR-339-5p inhibits metastasis of non-small cell lung cancer by regulating the epithelial-to-mesenchymal transition. Oncol Lett. 15:2508–2514. 2018.PubMed/NCBI View Article : Google Scholar
7	Xu J, Pan X and Hu Z: MiR-502 mediates esophageal cancer cell TE1 proliferation by promoting AKT phosphorylation. Biochem Biophys Res Commun. 501:119–123. 2018.PubMed/NCBI View Article : Google Scholar
8	Li J, Liang Y, Lv H, Meng H, Xiong G, Guan X, Chen X, Bai Y and Wang K: miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway. Gene. 625:1–9. 2017.PubMed/NCBI View Article : Google Scholar
9	Qiu Z, Li H, Wang J and Sun C: miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. Oncol Rep. 38:2735–2740. 2017.PubMed/NCBI View Article : Google Scholar
10	Song Y, Guo Q, Gao S and Hua K: miR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3. Biochem Biophys Res Commun. 516:872–879. 2019.PubMed/NCBI View Article : Google Scholar
11	Jiang K, Zhao T, Shen M, Zhang F, Duan S, Lei Z and Chen Y: MiR-940 inhibits TGF-β-induced epithelial-mesenchymal transition and cell invasion by targeting Snail in non-small cell lung cancer. J Cancer. 10:2735–2744. 2019.PubMed/NCBI View Article : Google Scholar
12	Ji Y, Han Z, Shao L and Zhao Y: Ultrasound-targeted microbubble destruction of calcium channel subunit alpha 1D siRNA inhibits breast cancer via G protein-coupled receptor 30. Oncol Rep. 36:1886–1892. 2016.PubMed/NCBI View Article : Google Scholar
13	Chen H and Hwang JH: Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors. J Ther Ultrasound. 1(10)2013.PubMed/NCBI View Article : Google Scholar
14	Tinkov S, Bekeredjian R, Winter G and Coester C: Microbubbles as ultrasound triggered drug carriers. J Pharm Sci. 98:1935–1961. 2009.PubMed/NCBI View Article : Google Scholar
15	Tu J, Zhang H, Yu J, Liufu C and Chen Z: Ultrasound-mediated microbubble destruction: A new method in cancer immunotherapy. Onco Targets Ther. 11:5763–5775. 2018.PubMed/NCBI View Article : Google Scholar
16	Wu J and Li RK: Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases. Genes Dis. 4:64–74. 2017.PubMed/NCBI View Article : Google Scholar
17	Loriot A, Van Tongelen A, Blanco J, Klaessens S, Cannuyer J, van Baren N, Decottignies A and De Smet C: A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics. 9:1163–1171. 2014.PubMed/NCBI View Article : Google Scholar
18	Thienpont B, Galle E and Lambrechts D: TET enzymes as oxygen-dependent tumor suppressors: Exciting new avenues for cancer management. Epigenomics. 8:1445–1448. 2016.PubMed/NCBI View Article : Google Scholar
19	Zhang K and Guo L: MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. Gene. 641:272–278. 2018.PubMed/NCBI View Article : Google Scholar
20	Zhang J, Xu S, Xu J, Li Y, Zhang J, Zhang J and Lu X: miR7675p inhibits glioma proliferation and metastasis by targeting SUZ12. Oncol Rep. 42:55–66. 2019.PubMed/NCBI View Article : Google Scholar
21	Leong-Poi H, Kuliszewski MA, Lekas M, Sibbald M, Teichert-Kuliszewska K, Klibanov AL, Stewart DJ and Lindner JR: Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Circ Res. 101:295–303. 2007.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Yang L, Dou Y, Sui Z, Cheng H, Liu X, Wang Q, Gao P, Qu Y and Xu M: Upregulated miRNA-182-5p expression in tumor tissue and peripheral blood samples from patients with non-small cell lung cancer is associated with downregulated Caspase 2 expression. Exp Ther Med. 19:603–610. 2020.PubMed/NCBI View Article : Google Scholar
24	Huang L, Tang X, Shi X and Su L: miR-532-5p promotes breast cancer proliferation and migration by targeting RERG. Exp Ther Med. 19:400–408. 2020.PubMed/NCBI View Article : Google Scholar
25	Zhang J, Kong X, Shi Q and Zhao B: MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer. Cancer Biomark: Dec. 24:2019.doi: 10.3233/CBM-190704 (Epub ahead of print). PubMed/NCBI View Article : Google Scholar
26	Biswas S: MicroRNAs as therapeutic agents: The future of the battle against cancer. Curr Top Med Chem. 18:2544–2554. 2018.PubMed/NCBI View Article : Google Scholar
27	Azarbarzin S, Hosseinpour Feizi MA, Safaralizadeh R, Ravanbakhsh R, Kazemzadeh M, Fateh A, Karimi N and Moaddab Y: The value of miR-299-5p in diagnosis and prognosis of Intestinal-type gastric adenocarcinoma. Biochem Genet. 54:413–420. 2016.PubMed/NCBI View Article : Google Scholar
28	Zheng W, Zhao J, Tao Y, Guo M, Ya Z, Chen C, Qin N, Zheng J, Luo J and Xu L: MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer. Oncol Lett. 16:2777–2782. 2018.PubMed/NCBI View Article : Google Scholar
29	Bagheri A, Khorram Khorshid HR, Mowla SJ, Mohebbi HA, Mohammadian A, Yaseri M, Solaymani-Dodaran M, Sherafatian M and Tavallaie M: Altered miR-223 expression in sputum for diagnosis of Non-small cell lung cancer. Avicenna J Med Biotechnol. 9:189–195. 2017.PubMed/NCBI
30	Sromek M, Glogowski M, Chechlinska M, Kulinczak M, Szafron L, Zakrzewska K, Owczarek J, Wisniewski P, Wlodarczyk R, Talarek L, et al: Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol (Dordr). 40:529–536. 2017.PubMed/NCBI View Article : Google Scholar
31	Wang SY, Li Y, Jiang YS and Li RZ: Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:4092–4097. 2017.PubMed/NCBI
32	Ow SH, Chua PJ and Bay BH: miR-149 as a potential molecular target for cancer. Curr Med Chem. 25:1046–1054. 2018.PubMed/NCBI View Article : Google Scholar
33	Kang X, Kong F, Wu S, Liu Q, Yang C, Wu X and Zhang W: microRNA-612 suppresses the malignant development of non-small-cell lung cancer by directly targeting bromodomain-containing protein 4. Onco Targets Ther. 12:4167–4179. 2019.PubMed/NCBI View Article : Google Scholar
34	Ling C, Wang X, Zhu J, Tang H, Du W, Zeng Y, Sun L, Huang JA and Liu Z: MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer. Cancer Me. 8:3520–3531. 2019.PubMed/NCBI View Article : Google Scholar
35	Feng Y, Zhang L, Wu J, Khadka B, Fang Z, Gu J, Tang B, Xiao R, Pan G and Liu J: CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. J Exp Clin Cancer Res. 38(54)2019.PubMed/NCBI View Article : Google Scholar
36	Wang TY, Choe JW, Pu K, Devulapally R, Bachawal S, Machtaler S, Chowdhury SM, Luong R, Tian L, Khuri-Yakub B, et al: Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. J Control Release. 203:99–108. 2015.PubMed/NCBI View Article : Google Scholar
37	Lin L, Fan Y, Gao F, Jin L, Li D, Sun W, Li F, Qin P, Shi Q, Shi X and Du L: UTMD-promoted Co-delivery of gemcitabine and miR-21 inhibitor by Dendrimer-entrapped gold nanoparticles for pancreatic cancer therapy. Theranostics. 8:1923–1939. 2018.PubMed/NCBI View Article : Google Scholar
38	Ji Y, Han Z, Shao L and Zhao Y: Evaluation of in vivo antitumor effects of low-frequency ultrasound-mediated miRNA-133a microbubble delivery in breast cancer. Cancer Med. 5:2534–2543. 2016.PubMed/NCBI View Article : Google Scholar
39	Qin D, Li H and Xie H: Ultrasoundtargeted microbubble destructionmediated miR205 enhances cisplatin cytotoxicity in prostate cancer cells. Mol Med Rep. 18:3242–3250. 2018.PubMed/NCBI View Article : Google Scholar
40	Park SJ, Lee BR, Kim HS, Ji YR, Sung YH, ShikChoi K, Park HD, Kim SH, Kim MO and Ryoo ZY: Inhibition of migration and invasion by Tet-1 overexpression in human lung carcinoma H460 cells. Oncol Res. 23:89–98. 2016.PubMed/NCBI View Article : Google Scholar